Motor and Non-motor Complications Following Different Early Therapies in Parkinson’s Disease

People living with Parkinson’s disease (PD) often start their treatment with one of three main medication types: 1) Levodopa 2) Dopamine agonists 3) Monoamine oxidase inhibitors (MAOIs) These can be used on their own or in combination. But until now, we haven’t had much real-world data on how these treatments work in the early stages of the disease. 🔬 What Did the Study Look At? Researchers in France studied 1,722 people with PD from a national research group called NS-PARK. Everyone had been diagnosed for less than five years and had no motor complications when they entered the study. The goal was to understand how different early treatment strategies affect the chances of developing: Involuntary movements (dyskinesia) Motor fluctuations Impulse control issues (like compulsive gambling or shopping) Apathy (loss of motivation or interest) Hallucinations or psychosis Daytime sleepiness 💊 What Treatment Types Were Compared? Participants were divided into three groups based on their medication: Levodopa alone Levodopa alternatives (such as dopamine agonists or MAOIs) Levodopa combined with other therapies 📈 Key Findings ✅ Lower risk of involuntary movements: People who started with levodopa alternatives had a lower chance of developing dyskinesia than those who started with levodopa alone. ⚖️ No major difference in motor fluctuations between the treatment groups. ⚠️ Higher risk of impulse control problems (e.g., gambling, compulsive spending) in those taking levodopa alternatives or combination therapies. 🌟 Lower risk of apathy in those taking levodopa alternatives or combinations compared to levodopa alone. 🚫 No clear link between any treatment type and hallucinations, psychosis, or daytime sleepiness. 🤝 Why This Matters This study shows that starting treatment with levodopa alternatives may help reduce some complications (like involuntary movements and apathy), but they may increase the risk of others (like impulse control issues). These insights can help people with Parkinson’s and their healthcare teams make more informed decisions based on individual needs and preferences.